MSTN and cancer: In particular, systemic overexpression of myostatin has been shown to induce profound muscle loss (26), and increased MSTN levels in serum have been observed in disease states such as cancer, acquired immunodeficiency syndrome, chronic kidney failure, and heart failure (5, 8, 9, 22).